Investing.com - Financial Markets Worldwide

Genor Biopharma Holdings Ltd (6998)

Hong Kong
Currency in HKD
3.60
-0.24(-6.25%)
Closed·
6998 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
6998 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
3.453.85
52 wk Range
1.234.05
Key Statistics
Edit
Bid/Ask
3.59 / 3.60
Prev. Close
3.84
Open
3.85
Day's Range
3.45-3.85
52 wk Range
1.23-4.05
Volume
2.57M
Average Volume (3m)
1.47M
1-Year Change
179.07%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
6998 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 17
Net income is expected to grow this year
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Genor Biopharma Holdings Ltd Company Profile

Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company’s principal drug candidates include GB242, an infliximab (Remicade) biosimilar for rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, and Crohn’s disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for breast cancer; and GB492, a stimulator of interferon genes combined with GB226, currently under Phase 1/2 clinical trial to treat solid tumours. It also develops GB226, which is in Phase III clinical trial; GB261, which is in Phase I/II clinical trial for NHL; and GB263T that is in Phase I/II clinical trial for NSCLC. In addition, the company develops GB221, which is in Phase III clinical trial for HER2+ 1L/2L+ mBC; GB223 that is in Phase I clinical trial for GCTB, PMO; GB241 that is in Phase III clinical trial for 1L DLBCL; and GB251, which is in Phase I clinical trial for HER2+ 1L/2L+ mBC. Further, the company’s product candidates that are in pre-clinical trials include GB262, GB264, GB266, GB267, and GB268 for cancer treatment. The company was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
24
Market
Hong Kong

Compare 6998 to Peers and Sector

Metrics to compare
6998
Peers
Sector
Relationship
P/E Ratio
−33.6x−15.9x−0.5x
PEG Ratio
−0.360.300.00
Price/Book
1.5x6.3x2.6x
Price / LTM Sales
8.4x23.7x3.3x
Upside (Analyst Target)
-2.2%43.5%
Fair Value Upside
Unlock−16.0%6.8%Unlock

Earnings

Latest Release
Apr 24, 2025
EPS / Forecast
0.14 / --
Revenue / Forecast
191.76M / --
EPS Revisions
a
a
Unlock
Last 90 days

6998 Income Statement

FAQ

What Stock Exchange Does Genor Biopharma Holdings Trade On?

Genor Biopharma Holdings is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for Genor Biopharma Holdings?

The stock symbol for Genor Biopharma Holdings is "6998."

What Is the Genor Biopharma Holdings Market Cap?

As of today, Genor Biopharma Holdings market cap is 1.88B.

What Is Genor Biopharma Holdings's Earnings Per Share (TTM)?

The Genor Biopharma Holdings EPS (TTM) is -0.10.

From a Technical Analysis Perspective, Is 6998 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Genor Biopharma Holdings Stock Split?

Genor Biopharma Holdings has split 0 times.

How Many Employees Does Genor Biopharma Holdings Have?

Genor Biopharma Holdings has 24 employees.

What is the current trading status of Genor Biopharma Holdings (6998)?

As of 09 Aug 2025, Genor Biopharma Holdings (6998) is trading at a price of 3.60, with a previous close of 3.84. The stock has fluctuated within a day range of 3.45 to 3.85, while its 52-week range spans from 1.23 to 4.05.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.